| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $40,892,265 | 32 | 100 |
| Chen Wan-Shan | director | 0 | $0 | 1 | $198,473 | $-198,473 |
| MATA NATHAN L. | Chief Scientific Officer | 0 | $0 | 20 | $2.94M | $-2.94M |
| Scholl Hendrik Peter | Chief Medical Officer | 0 | $0 | 3 | $2.94M | $-2.94M |
| Chuang Hao-Yuan | Chief Financial Officer | 0 | $0 | 4 | $14M | $-14M |
| Lin Yu-Hsin | Chief Executive Officer | 0 | $0 | 4 | $20.82M | $-20.82M |
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular …
Over the last 12 months, insiders at Belite Bio, Inc have bought $0 and sold $40.89M worth of Belite Bio, Inc stock.
On average, over the past 5 years, insiders at Belite Bio, Inc have bought $0 and sold $40.89M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-01 | Sale | Scholl Hendrik Peter | Chief Medical Officer | 500 0.0013% | $165.32 | $82,659 | -6.36% | |
| 2026-09-08 | Sale | Lin Yu-Hsin | Chief Executive Officer | 26,000 0.0659% | $196.56 | $5.11M | -18.42% | |
| 2026-09-08 | Sale | Chuang Hao-Yuan | Chief Financial Officer | 17,962 0.0455% | $196.42 | $3.53M | -18.42% | |
| 2026-09-04 | Sale | Lin Yu-Hsin | Chief Executive Officer | 74,435 0.1796% | $187.71 | $13.97M | -18.09% | |
| 2026-09-04 | Sale | Chuang Hao-Yuan | Chief Financial Officer | 49,433 0.1192% | $187.64 | $9.28M | -18.09% | |
| 2026-08-12 | Sale | Lin Yu-Hsin | Chief Executive Officer | 365 0.0009% | $180.35 | $65,827 | -10.52% | |
| 2026-08-12 | Sale | Chuang Hao-Yuan | Chief Financial Officer | 367 0.0009% | $180.35 | $66,187 | -10.52% | |
| 2026-06-18 | Sale | Scholl Hendrik Peter | Chief Medical Officer | 10,000 0.0248% | $145.24 | $1.45M | +7.24% | |
| 2026-06-16 | Sale | Scholl Hendrik Peter | Chief Medical Officer | 10,000 0.0254% | $140.57 | $1.41M | +13.39% | |
| 2026-05-07 | Sale | MATA NATHAN L. | Chief Scientific Officer | 666 0.0016% | $153.21 | $102,039 | -1.28% | |
| 2026-05-06 | Sale | MATA NATHAN L. | Chief Scientific Officer | 1,000 0.0025% | $153.84 | $153,839 | -1.40% | |
| 2026-05-05 | Sale | MATA NATHAN L. | Chief Scientific Officer | 120 0.0003% | $153.92 | $18,471 | -0.09% | |
| 2026-05-05 | Sale | MATA NATHAN L. | Chief Scientific Officer | 1,000 0.0025% | $155.50 | $155,502 | -0.09% | |
| 2026-05-04 | Sale | MATA NATHAN L. | Chief Scientific Officer | 1,000 0.0025% | $155.64 | $155,636 | -0.08% | |
| 2026-05-01 | Sale | MATA NATHAN L. | Chief Scientific Officer | 1,000 0.0025% | $155.78 | $155,778 | -0.28% | |
| 2026-04-30 | Sale | MATA NATHAN L. | Chief Scientific Officer | 1,000 0.0025% | $156.97 | $156,973 | -2.96% | |
| 2026-04-29 | Sale | MATA NATHAN L. | Chief Scientific Officer | 1,000 0.0025% | $155.82 | $155,817 | -0.02% | |
| 2026-04-28 | Sale | MATA NATHAN L. | Chief Scientific Officer | 1,000 0.0025% | $159.16 | $159,162 | -2.67% | |
| 2026-04-27 | Sale | MATA NATHAN L. | Chief Scientific Officer | 555 0.0014% | $161.87 | $89,840 | -5.25% | |
| 2026-04-27 | Sale | MATA NATHAN L. | Chief Scientific Officer | 1,000 0.0025% | $162.64 | $162,641 | -5.25% |
| Increased Positions | 57 | +190% | 6M | +257.11% |
| Decreased Positions | 14 | -46.67% | 971,123 | -42.47% |
| New Positions | 39 | New | 4M | New |
| Sold Out Positions | 4 | Sold Out | 322,619 | Sold Out |
| Total Postitions | 73 | +143.33% | 7M | +214.64% |